TIZIANA LIFE SCIENCES LTD (TLSA)
BMG889121031 - Common Stock
Overall TLSA gets a fundamental rating of 2 out of 10. We evaluated TLSA against 588 industry peers in the Biotechnology industry. While TLSA seems to be doing ok healthwise, there are quite some concerns on its profitability. TLSA does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year TLSA has reported negative net income.
TLSA had a negative operating cash flow in the past year.
In the past 5 years TLSA always reported negative net income.
TLSA had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
TLSA has a Return On Assets of -58.12%. This is comparable to the rest of the industry: TLSA outperforms 43.49% of its industry peers.
With a Return On Equity value of -78.64%, TLSA perfoms like the industry average, outperforming 52.57% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -58.12% | ||
| ROE | -78.64% | ||
| ROIC | N/A |
ROA(3y)-47.66%
ROA(5y)-129.15%
ROE(3y)-59.06%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for TLSA so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The number of shares outstanding for TLSA remains at a similar level compared to 1 year ago.
TLSA has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, TLSA has a worse debt to assets ratio.
2.2 Solvency
An Altman-Z score of 6.85 indicates that TLSA is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 6.85, TLSA belongs to the top of the industry, outperforming 83.90% of the companies in the same industry.
TLSA has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
TLSA has a Debt to Equity ratio (0.01) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 6.85 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
TLSA has a Current Ratio of 3.65. This indicates that TLSA is financially healthy and has no problem in meeting its short term obligations.
TLSA's Current ratio of 3.65 is in line compared to the rest of the industry. TLSA outperforms 41.44% of its industry peers.
TLSA has a Quick Ratio of 3.65. This indicates that TLSA is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 3.65, TLSA perfoms like the industry average, outperforming 42.47% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.65 | ||
| Quick Ratio | 3.65 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 44.44% over the past year.
EPS 1Y (TTM)44.44%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-150%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A
3.2 Future
The Earnings Per Share is expected to grow by 17.49% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y59.46%
EPS Next 2Y28.4%
EPS Next 3Y17.49%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
TLSA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year TLSA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as TLSA's earnings are expected to grow with 17.49% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.4%
EPS Next 3Y17.49%
5. Dividend
5.1 Amount
No dividends for TLSA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TIZIANA LIFE SCIENCES LTD
NASDAQ:TLSA (4/26/2024, 7:19:52 PM)
After market: 0.7896 +0.01 (+1.22%)0.7801
-0.06 (-7.25%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap79.78M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -58.12% | ||
| ROE | -78.64% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.65 | ||
| Quick Ratio | 3.65 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)44.44%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y59.46%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y